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ABSTRACT
Introduction: Clinical trials have demonstrated
the efficacyof all-oraldirect-acting antiviral (DAA)
regimens in the treatment of patients infected
with hepatitis C virus (HCV). This study assessed
real-world effectiveness of two recently approved
regimens; paritaprevir/ritonavir/ombitasvir;
dasabuvir (3D), and sofosbuvir/ledipasvir (SOF/
LDV) in patients with HCV genotype 1.
Methods: A retrospective analysis of
administrative claims data (IMS Health
Patient-Centric Data Warehouse/Medivo
database) from October 1, 2013 to August 14,
2015wasconducted.PatientsC19 yearsofagewith
a HCV genotype 1 infection, a prescription fill for
3D or SOF/LDV, and C1 HCV viral load (VL)
assessment from weeks 4–30 post-treatment were
selected for analysis. Percentages of patients
achieving sustained virologic response (SVR;
defined as HCV RNA B43 IU/mL) were
determined. Unadjusted SVR rates were
compared between treatment groups using
Fisher’s exact tests. SVR rates were also assessed
using multivariate regression with adjustment for
age group, sex, and treatment history. Analyses
were repeated for a subset of patients with VL
assessment from 12 to 30 weeks post-treatment.
Results: A total of 1707 (44 3D and 1663 SOF/
LDV) patientswere included. Themajority (60%)
were male, 49% were aged 55–64 years, and 97%
were treatment-naı¨ve 1 year prior to index. The
unadjusted relative risk (RR) for achieving SVR in
patients treated with SOF/LDV compared with
3D was 0.98%, 95% confidence interval (CI):
0.93–1.02. After adjusting for the baseline
covariates, the RRwas 0.98%, 95%CI: 0.94–1.03.
Conclusions: In this early view of real-world
data, effectiveness of all-oral DAA regimens in
HCV genotype 1 patients was concordant with
results from registration trials. SVR rates were
similar for the two regimens. Further studies are
needed to confirm these results.
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INTRODUCTION
Chronic hepatitis C (CHC) is a progressive liver
disease caused by infection with the hepatitis C
virus (HCV). CHC affects approximately
130–150 million people globally, and up to
500,000 people die each year from liver
diseases associated with CHC [1]. In the
United States (US), approximately 3 million
individuals are infected with HCV.
Approximately, 75% of these infections are
attributed to HCV genotype 1 [2]. The
first-generation direct-acting antivirals (DAAs)
include the NS3/4A serine protease inhibitors
telaprevir and boceprevir, and the NS5B
ribonucleic acid (RNA) polymerase inhibitor
sofosbuvir. Clinical trials demonstrated that
use of these DAAs in combination with
peginterferon and ribavirin was associated
with sustained virologic response (SVR) in up
to 75% (telaprevir and boceprevir) to 90%
(sofosbuvir) of patients with HCV genotype 1
infection [3]. However, results of real-world
studies of these regimens have been discordant
with those of the clinical trials. For example,
SVR rates in real-world studies of telaprevir have
been reported at 44–52%, and at 72% for older
sofosbuvir-based regimens [4–6].
The second-generation DAA regimens
paritaprevir/ritonavir/ombitasvir; dasabuvir
(3D) and sofosbuvir/ledipasvir (SOF/LDV) were
approved by the US Food and Drug
Administration (FDA) for patients with HCV
genotype 1. These all-oral regimens have been
associated with improved efficacy, safety,
tolerability, and shorter durations when
compared to first-generation protease inhibitor
regimens [3, 7]. Additionally, these newer
regimens have been shown to be cost-effective
across all fibrosis stages [8, 9]. Clinicians and
payers have anticipated the demonstration of
real-world effectiveness of these new DAA
regimens. However, reports available to date
are limited to data describing the effectiveness
of individual therapies, and are only in abstract
form. Most recently, real-world data from
Poland demonstrated 98% SVR12 with 3D [10].
This report presents the first analysis of the US
real-world effectiveness of these new HCV
treatment regimens as measured by SVR rates
captured from a large pharmacy and laboratory
claims database.
METHODS
An analysis of the IMS Health Patient-Centric
Data Warehouse/Medivo database from October
1, 2013 to August 14, 2015 was conducted to
compare real-world SVR rates among patients
treated with 3D and SOF/LDV. Data were
obtained from the IMS Health Patient-Centric
Data Warehouse (Alexandria, VA, USA), with
approximately 240 million patients in the
pharmacy database, integrated with medical
and laboratory claims (Medivo laboratory
data). The IMS database contains de-identified,
longitudinal, patient-level records, including
clinical and demographic information (e.g.,
age, sex, and comorbidities), inpatient and
outpatient medical claims (e.g., admission and
discharge dates and procedure and diagnosis
codes, laboratory tests), and pharmacy claims
data (e.g., drug dispensed based on national
drug codes, quantity and date dispensed, drug
strength, and days’ supply).
This was a real-world study; the observation
period was selected based on the FDA approval
dates of the new DAAs (October 2014 and
December 2014 for SOF/LDV and 3D,
respectively) plus 1 year previous to assess
baseline characteristics (age, sex, treatment
history, and comorbidities). Patients were
eligible if they received C1 prescription fill of
3D (with or without ribavirin) or SOF/LDV from
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October 1, 2014, through August 14, 2015, were
C19 years of age, had adiagnosis ofCHC (with an
HCV genotype test confirming genotype 1), and
had C1 HCV RNA test from week 4 to week 30
post-treatment to determine viral eradication.
Patients were excluded if they had a prescription
filled for both DAAs, had a non-genotype-1 (or
unknown genotype) infection, or had no record
of anHCVRNA test during the week 4 toweek 30
post-treatment period. The index date was
defined as the first DAA regimen prescription
fill date (Fig. 1). End of treatment (EOT) was
defined as the last DAA fill date plus number of
days supplied. SVR was categorized qualitatively
as detectable or undetectable or quantitatively
based on HCV RNA result of B43 IU/mL
(undetectable) and[43 IU/mL (detectable). For
this report, SVR rates were collected from
post-treatment weeks 4–30. If[1 HCV RNA lab
assessment was available, the result closest to
30 weeks post-treatment was used. Time to
post-treatment HCV RNA determination is the
physician’s decision, and may not be related to
HCV treatment.
Baseline sociodemographic characteristics,
1-year prior treatment history, and
comorbidities were summarized using
descriptive statistics; Chi-square and Fisher’s
exact tests were used to assess differences
between treatment groups. The distribution of
HCV RNA testing over time among patients in
the sample was also assessed descriptively, using
medians and interquartile range to describe the
distributions. Two patient groups were defined;
those with C1 viral load assessment during the
4- to 30-week follow-up period (primary
analysis of SVR rates), and a subgroup with an
assessment from 12 to 30 weeks (ad hoc
analysis) representing SVR12, the commonly
accepted reference for cure American
Association for the Study of Liver Disease/
Infectious Diseases Society of America (AASLD/
IDSA) [11]. SVR rates were examined using
descriptive statistics, and differences in SVR
rates between treatment groups were assessed
using Fisher’s exact tests. SVR rates were also
assessed using multivariate logistic regression
analysis, controlling for age group, sex, and
Fig. 1 Study design. The index date was deﬁned as the date
of the ﬁrst prescription ﬁll for 3D or SOF/LDV. Baseline
characteristics were assessed in the year prior to the index
date. The primary analysis included patients with a viral
load assessment from 4 to 30 weeks following EOT. An ad
hoc analysis was limited to patients with a viral load
assessment from 12 to 30 weeks following EOT. 3D
Paritaprevir/ritonavir/ombitasvir; dasabuvir, DAA
direct-acting antiviral, EOT End of treatment, SOF/LDV
Sofosbuvir/ledipasvir, VL Viral load, wks weeks
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treatment history. Results were summarized
using parameter estimates (b) and standard
errors. A priori, P values\0.05 were considered
statistically significant. Statistical analysis was
performed with the use of SAS 9.3 for Windows
XP (SAS Institute Inc. Cary, NC, USA).
This study was based on administrative
claims data, and does not contain any new
studies with human or animal subjects
performed by any of the authors.
RESULTS
A total of 55,871 patients in the database
received a prescription for 3D (n = 2174) and/
or SOF/LDV (n = 53,697) during the study
period (Fig. 2). Of these, 169 were excluded
because of a prescription for both DAAs, and 13
(3D) and 592 (SOF/LDV) were exclude for age
\19 years of age. Of the remaining 54,928
patients, 18.5% (n = 369, 3D) and 18.2%
(n = 9643, SOF/LDV) had a genotype test
available in the database, of which 98.6%
(n = 364, 3D) and 98.1% (n = 9461, SOF/LDV)
were genotype 1. Of these, 181 (3D) and 5755
(SOF/LDV) patients in the 4–30 weeks cohort
finished HCV treatment and were eligible for
determining EOT; 161 (3D) and 5230 (SOF/
LDV) had C4 weeks of follow-up from EOT; and
44 (3D) and 1663 (SOF/LDV) had at least one
Fig. 2 Deﬁnition of patient sample. Data source: IMS
Health Patient-Centric Data Warehouse/Medivo database,
October 2013 to August 2015. 3D paritaprevir/ritonavir/
ombitasvir; dasabuvir, DAA direct-acting antiviral, EOT
end of treatment, HCV hepatitis C virus, SOF/LDV
sofosbuvir/ledipasvir, VL viral load
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viral load between weeks 4 and 30
post-treatment. For the 12–30 weeks cohort, 71
(3D) and 3279 (SOF/LDV) had C12 weeks of
follow-up from EOT and 15 (3D) and 862 (SOF/
LDV) had at least one viral load between weeks
12 and 30 post-treatment.
Baseline characteristics of the patients in
each treatment group were similar (Table 1).
The majority (60%) of patients were male, and
nearly half (49%) were aged 55–64 years. In
addition, the majority (97%) of patients have
not received HCV treatment in the year prior to
Table 1 Baseline characteristics for patients with HCV genotype 1 treated with 3D and SOF/LDV
Characteristic Treatment regimen P value
3D, n (%) SOF/LDV, n (%)
Male 23 (52.3) 1001 (60.2) 0.4811
Age group (years) 0.2483
19–29 3 (6.8) 36 (2.2)
30–44 3 (6.8) 110 (6.6)
45–54 5 (11.4) 295 (17.7)
55–64 25 (56.8) 810 (48.7)
65–79 8 (18.2) 395 (23.8)
80? 0 (0.0) 17 (1.0)
1-year prior treatment historya 1.0000
Treatment-naı¨ve 43 (97.7) 1605 (96.5)
Treatment-experienced 1 (2.3) 58 (3.5)
Comorbiditiesb
Renal 2 (18.2) 49 (8.2) 0.2320
Diabetes 4 (36.4) 216 (36.0) 1.0000
Cirrhosis 1 (9.1) 216 (36.0) 0.1076
Cardiovascular 3 (27.3) 80 (13.3) 0.1780
Psychosis/depression 1 (9.1) 45 (7.5) 0.5804
Anemia 2 (18.2) 100 (16.7) 1.0000
Liver transplant 0 (0.0) 0 (0.0) –
Gastrointestinal 5 (45.5) 143 (23.8) 0.1465
Obesity 0 (0.0) 76 (12.7) 0.3754
3D paritaprevir/ritonavir/ombitasvir; dasabuvir, SOF/LDV sofosbuvir/ledipasvir
a Treatment history: in the 1 year prior to the start of 3D or SOF/LDV, any one of the following combinations:
peginterferon plus ribavirin; telaprevir plus peginterferon plus ribavirin; boceprevir plus peginterferon plus ribavirin;
sofosbuvir plus simeprevir with or without ribavirin; sofosbuvir plus ribavirin; sofosbuvir plus peginterferon plus ribavirin;
simeprevir plus peginterferon plus ribavirin
b Comorbidities were present in n = 611 (n = 11 3D; n = 600 SOF/LDV) of patients overall. Some patients had C1
comorbidity
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the index date. Not all patients in the IMS
database could be linked with the Medivo
Laboratory database; therefore, only 36%
(n = 611) of these patients had comorbidities
listed. Comorbidities were based on
International Statistical Classification of
Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes and were assessed 1 year prior
to treatment. Gastrointestinal disorders and
diabetes were the most common comorbidities
in 3D and diabetes and cirrhosis were the most
common comorbidities in SOF/LDV. Among
patients with comorbidities listed, no patients
in the sample had received a liver transplant.
No significant differences in comorbidities were
found between treatment groups.
The distribution of HCV RNA tests over the
follow-up period is illustrated in Fig. 3. The
median time of SVR assessment was
approximately 12 weeks (85 days) following
the EOT for patients who received SOF/LDV,
and approximately 9 weeks (61 days) for those
who received 3D. HCV RNA test distributions
were 42 vs. 49 days (1st quartiles) and 95 vs.
108 days (3rd quartiles), for 3D and SOF/LDV,
respectively (Fig. 3A). Among 877 patients with
a viral load assessment from 12 to 30 weeks
following the EOT (n = 15 for 3D; n = 862 for
SOF/LDV), the median time of assessment was
approximately 15 weeks for patients in both
groups (Fig. 3b).
As illustrated in Fig. 4, the majority of
patients with a viral load assessment achieved
SVR in each treatment group. When including
latest viral load assessed within 4–30 weeks
post-treatment, unadjusted SVR rates were
98% and 96% for patients who received 3D
and SOF/LDV, respectively (Fig. 4). An ad hoc
analysis of patients with a viral load assessment
from 12 to 30 weeks post-treatment showed
unadjusted SVR rates of 100% and 95% for 3D
and SOF/LDV, respectively. The differences in
SVR rates between treatment groups were not
statistically significant (P = 1.0). Results of
multivariate analyses controlling for age
group, sex, and treatment history confirmed
that SVR rates (parameter estimate -0.017,
P = 0.5032) were not statistically significant for
patients assessed from 4 to 30 weeks
post-treatment (Table 2). However, ad hoc
analysis of SVR from 12 to 30 weeks
demonstrated that patients treated with SOF/
LDV were 8.4% less likely to achieve SVR than
those treated with 3D (parameter estimate
-0.084, P\0.0001). The unadjusted relative
risk (RR) for achieving SVR in patients treated
with SOF/LDV compared with 3D was 0.98%,
95% confidence interval (CI): 0.93–1.02. After
adjusting for the baseline covariates, the RR was
0.98%, 95% CI: 0.94–1.03 (Table 3).
DISCUSSION
Results from controlled clinical trials have
suggested that the emergence of novel, all-oral
DAA regimens holds the promise of achieving
much higher rates of SVR among patients
infected with HCV than was possible with
previous treatments, with improved efficacy
and tolerability, and reduced treatment
duration [12–19]. This is the first report of the
effectiveness as measured by post-treatment
SVR rates associated with both 3D and SOF/
LDV in a real-world setting.
Fig. 3 Distributions of HCV RNA tests over time
following treatment. 3D paritaprevir/ritonavir/ombitasvir;
dasabuvir, HCV hepatitis C virus, RNA ribonucleic acid,
SOF/LDV sofosbuvir/ledipasvir, SVR sustained virologic
response
c
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This early view of effectiveness was
concordant with overall SVR12 [95%
demonstrated in clinical trials involving both
of these treatments ([12, 13]; Abbvie, data on
file). SVR12 is currently the most common
endpoint used in clinical trials of novel HCV
treatments, and was the assessment used in the
pivotal trials involving both 3D and SOF/LDV.
However, we found that in this real-world
analysis of claims data, the timing of HCV
RNA assessments seems to vary. In addition,
SVR24 was previously used as the primary
endpoint for registration studies; however,
regulatory agencies now accept an earlier
post-treatment virologic assessment, SVR12, for
approval of new regimens [20]. To capture all
available post-treatment SVR, the observation
period was extended to 30 weeks. Available data
suggest that a virologic assessment at 4 weeks
predicts SVR12, since studies have demonstrated
a high degree of concordance among SVR4,
SVR12, and SVR24. A study by Chen et al. [20]
established positive predictive values of 99%
and 94% for prediction of SVR24 from SVR12 and
SVR4, respectively, among subjects with HCV
genotype 1 infection treated with DAAs. In
addition, identical rates of SVR4 and SVR12 were
reported in a recent study of patients with HCV
Fig. 4 Unadjusted SVR rates. 3D paritaprevir/ritonavir/
ombitasvir; dasabuvir, HCV hepatitis C virus, SOF/LDV
sofosbuvir/ledipasvir, SVR sustained virologic response
Table 2 Adjusted SVR rates for patients with HCV genotype 1 treated with 3D and SOF/LDV
Effect 4–30 weeks (n5 1707) 12–30 weeks (n5 877)
Parameter estimate
(SE)
P value Parameter estimate
(SE)
P value
SOF/LDV vs. 3D -0.017 (0.025) 0.5032 -0.084 (0.000) \0.0001
Female vs. male -0.004 (0.011) 0.7112 -0.008 (0.016) 0.6041
1-year prior treatment-naı¨ve
vs. treatment-experienced
0.053 (0.040) 0.1846 0.051 (0.053) 0.3333
Age group (vs. 65–79 years)
19–29 -0.018 (0.038) 0.6363 -0.040 (0.064) 0.5343
30–44 -0.039 (0.028) 0.1593 -0.009 (0.037) 0.8073
45–54 -0.021 (0.017) 0.216 -0.024 (0.028) 0.3976
55–64 -0.003 (0.012) 0.7843 0.008 (0.018) 0.6602
80? -0.091 (0.089) 0.309 -0.225 (0.270) 0.4057
Parameter estimate (b) and standard error (SE) from multivariable analysis controlling for age group, sex, and treatment
history are shown
3D paritaprevir/ritonavir/ombitasvir; dasabuvir, HCV hepatitis C virus, SOF/LDV sofosbuvir/ledipasvir, SVR sustained
virologic response
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genotype-1/HIV-1 coinfection treated with
concomitant 3D and HIV-1 antiretroviral
treatment [21]. Therefore, for this study, the
earliest time for assessment of SVR was 4 weeks
following the EOT. To accommodate real-world
variability in the timing of SVR assessment, this
study included SVR rates ranging from 4 weeks
to 30 weeks post-treatment. When multiple
viral load results were available, the result
closest to 30 weeks was used to reflect the
real-world SVR of the new DAAs. However,
since the AASLD/IDSA 2015 guidelines [11]
recommend the SVR rate to be collected at 12
or more weeks after completing treatment, we
also reported 12- to 30-week SVR rates. Due to
the early view of this data, limiting the SVR to
12–30 weeks resulted in a small sample size;
caution should be used in interpreting this
result. These results were shown to be in
concordance with the 4- to 30-week results.
In the4- to30-week cohort, themedian timeof
viral load testing was approximately 3 weeks
earlier for patients on 3D vs. those on SOF/LDV.
In contrast, the median time of testing in the 12-
to 30-week cohort was similar (\1 week
difference) for patients on both regimens. The
differences in these times may be a reflection of
the FDA approval dates and HCV treatment start
dates: The later in theobservationperiodapatient
begins HCV treatment, the lower the probability
they will be in the database long enough to have
an assessment at 4 or 12 weeks post-treatment.
This study is the first to assess the real-world
effectiveness of the new all-oral DAAs in the
treatment of HCV. A particular strength of the
study was its use of a large administrative claims
database, which captured a large cross section of
the US population. However, this study does
have limitations that should be considered in
the interpretation of these results. First, this is
an early-view study; sample size was limited
because the medications assessed have only
been recently approved. In addition, only
27.3% (44/161) of patients had a recorded lab
test during the study period, suggesting patients
may have not had enough time in the study to
measure an SVR. Genotype testing was limited
due to the integration of the pharmacy and
laboratory database, where approximately 18%
of the patients in the pharmacy database were
also in laboratory database. Therefore, the
limited sample size precluded assessments of
differences in patient subgroups of interest (e.g.,
HCV genotypes 1a vs. 1b, treatment-naı¨ve vs.
experienced, treatment duration, HCV/HIV-1
coinfection, fibrosis stage and presence of
cirrhosis, and other comorbidities such as
renal insufficiency) and may limit the ability
to minimize selection bias. Additional
limitations are common to studies using
Table 3 Unadjusted and adjusted RR of achieving SVR rates for patients with HCV genotype 1 treated
Effect 4–30 weeks 12–30 weeks
RR 95% CI RR 95% CI
Unadjusted: SOF/LDV vs. 3D 0.98 0.93–1.02 0.95 N/aa
Adjusted: SOF/LDV vs. 3D 0.98 0.94–1.03 0.92 N/aa
Relative risk adjusted for age group, sex, and treatment history are shown
3D Paritaprevir/ritonavir/ombitasvir; dasabuvir, HCV Hepatitis C virus, SOF/LDV Sofosbuvir/ledipasvir, SVR Sustained
virologic response, RR Relative risk, CI Conﬁdence interval
a Standard error is zero, therefore, no conﬁdence limits
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claims data. For example, this study was
conducted using an integrated medical,
pharmacy and laboratory claims database
linked with laboratory data. Because the data
were incompletely integrated, only 36% of the
patients with pharmacy and laboratory data
also had medical data for assessment of
comorbidities. Similarly, because this study
used a combination of databases, laboratory
data were captured for only a fraction of the
patients on the new DAA regimens, and
laboratory tests done outside the healthcare
system were not available. Because the
pre-treatment assessment period was limited to
1 year prior to index date, the number of
treatment-experienced patients may have been
underestimated. This early analysis included
only patients who had an available HCV RNA
test and would have excluded patients who
discontinued therapy without receiving a
post-treatment HCV RNA test. Among those
patients with more than one HCV RNA test
post-treatment, 100% of the 3D patients HCV
RNA results did not change from first to last
HCV RNA results, were as only 95% of SOF/LDV
HCV RNA results did not change. Finally,
despite the breadth of the patient population
assessed, uninsured patients were not included
in the database; therefore, our results may not
be fully generalizable to the full HCV
population. While this is an early view of SVR
rates in the real-world setting, further
investigation is needed with a more
comprehensive database and enough time in
the study to measure an SVR.
CONCLUSION
This is the first report on real-world SVR rates of
3D compared with SOF/LDV in HCV genotype 1
patients. No difference in real-world SVR rates
was observed between the two regimens in
patients with HCV genotype 1. Further studies
are needed to confirm these results.
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